PathAI Introduces AI-Powered MET Predict to Improve Lung Cancer Diagnostics
TL;DR
PathAI's AI-powered MET Predict provides a competitive advantage by identifying NSCLC tumors with potential genetic alterations, enhancing efficiency.
The integration of MET Predict into AISight utilizes AI to enhance efficiency of NSCLC tumor assessments by providing rapid and precise biomarker insights.
MET Predict has the potential to make the world a better place by significantly improving the efficiency of biomarker evaluation and molecular testing paradigms.
PathAI's launch of MET Predict on AISight represents a leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments.
Found this article helpful?
Share it with your network and spread the knowledge!
PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, has announced the launch of MET Predict on the AISight Image Management System (IMS). MET Predict is an AI-powered algorithm designed to assist pathologists in identifying non-small cell lung cancer (NSCLC) tumors that may exhibit MET exon 14 skipping (METex14) or MET amplification directly from an H&E whole slide image.
NSCLC accounts for approximately 85% of lung cancers, with 3-4% of these cases involving METex14. Currently, approved targeted therapies are available for NSCLC patients harboring METex14 mutations. Additionally, MET amplification occurs in 1-6% of NSCLC cases and is emerging as a significant biomarker in lung cancer.
Traditional methods for identifying MET alterations such as exon 14 skipping or amplification are often costly, time-consuming, and require specialized equipment and trained personnel. These factors limit the accessibility and scalability of molecular testing, highlighting the need for more efficient and cost-effective diagnostic methods.
“The integration of MET Predict into AISight marks a significant leap forward in utilizing AI to enhance the efficiency of NSCLC tumor assessments, particularly in identifying those with potential genetic alterations,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “By providing rapid and precise biomarker insights directly from H&E images, MET Predict equips pathologists with the essential information needed to drive timely and accurate NSCLC evaluations.”
MET Predict has the potential to significantly improve the efficiency of biomarker evaluation and molecular testing paradigms. The algorithm identifies over 90% of MET altered tumors while also providing insights that may preserve tissue in 30% of cases where the likelihood of MET alteration is low.
With the addition of MET Predict, AISight expands its toolset with the latest technology to assist pathologists in lung cancer assessments. This innovation addresses a crucial gap in pathology labs — the need for accessible, rapid, and comprehensive molecular tools that provide actionable insights from biopsy samples.
MET Predict and AISight are for Research Use Only and not intended for diagnostic procedures.
Curated from News Direct
